Prospect Biosystems has developed a broad-range biomarker discovery capability and an instrumentation platform, based upon its Edge ^TM (enhanced density gradient extraction) technology, providing rapid biology-based fractionation of complex tissue homogenate and cell lysate samples.

This major breakthrough in separation technology enables scientists involved in the discovery and development of pharmaceutical targets, diagnostics and therapeutics to:

• Rapidly characterize differences between diseased and healthy tissue;
• Significantly enrich low-abundance proteins from their crude extracts;
• Increase the reliability and specificity of downstream analyses;
• Easily identify and evaluate predictive, diagnostic and prognostic biomarkers;
• Facilitate clinical outcome prediction through the use of surrogate biomarkers, and;
• Develop rapid biomarker tests for clinical diagnosis and management.